STC1002

STC1002 is a preclinical-stage monoclonal antibody being developed by Staidson Pharma (specifically Staidson Hongkong) for the treatment of depression and other central nervous system (CNS) disorders. The drug targets brain-derived neurotrophic factor (BDNF), a key neurotrophin involved in neuronal survival, synaptic plasticity, and the regulation of mood. While the specific functional effect (agonist vs. antagonist) has not been publicly detailed, BDNF-modulating strategies in CNS research typically aim to restore neurotrophic support that is often diminished in chronic stress and depressive states. As a monoclonal antibody, STC1002 represents a targeted biologic approach to treating psychiatric conditions, which is distinct from traditional small-molecule antidepressants.